ABVC ABVC BioPharma, Inc: יחס שווי פעילות לרווח לפני ריבית, מסים ופחת

ABVC BioPharma (ABVC) develops proprietary plant-based treatments for ADHD and depression, the prospects of which depend on regulatory approval in the US and Taiwan. The business relies on targeted therapy with minimal side effects and the implementation of diagnostic systems. The current EV/EBITDA ratio is 0.00. The market capitalization trend on the GURU.Markets platform clearly demonstrates the valuation dynamics of this biopharmaceutical asset.

Given the significant clinical trial expenditures of ABVC BioPharma (ABVC) and its patent monetization model, the Enterprise Value to EBITDA ratio allows for a business valuation that accounts for debt load and depreciation. This chart reflects the real price of assets relative to operating profit, where a decline in the metric signals that the company is undervalued, while a prolonged minimum may indicate capital stagnation.